journal
MENU ▼
Read by QxMD icon Read
search

Clinical & Translational Oncology

journal
https://www.readbyqxmd.com/read/28741074/concurrent-chemoradiotherapy-with-weekly-nedaplatin-versus-radiotherapy-alone-in-elderly-patients-with-non-small-cell-lung-cancer
#1
F Chen, P Hu, N Liang, J Xie, S Yu, T Tian, Jingxin Zhang, G Deng, Jiandong Zhang
PURPOSE: We conduct this study to compare the efficacy and toxicity of intensity-modulated radiotherapy (IMRT) concurrent weekly nedaplatin (NDP) versus IMRT alone in the stage III/IV non-surgical elderly patients with non-small-cell lung cancer (NSCLC). METHODS: 117 patients were enrolled into our study. The patients were assigned into two different groups: radiotherapy (RT) group and chemoradiotherapy (CRT) group. Patients in RT group were treated with IMRT at a single daily dose of 2 Gy for 5 days per week, totally 52-66 Gy...
July 24, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28733866/inhibitory-effect-and-mechanism-of-mesenchymal-stem-cells-on-melanoma-cells
#2
J Zhang, L Hou, D Zhao, M Pan, Z Wang, H Hu, J He
PURPOSE: To explore the inhibitory effect and mechanism of MSCs on melanoma proliferation. METHODS: The inhibitory effect of MSCs on melanoma A375 cells was detected by co-culture and conditioned medium (CM) experiments using MTT method. The cell cycle was analyzed by flow cytometry. Then, Western Blot experiment detected the expression of proteins related to NF-κB signaling in A375 cells. The expression of IL-1Ra in MSCs was proved by RT-PCR. The over-expression and silencing vector pcDNA3...
July 21, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28726040/assessing-predicted-age-specific-breast-cancer-mortality-rates-in-27-european-countries-by-2020
#3
R Clèries, R M Rooney, M Vilardell, J A Espinàs, T Dyba, J M Borras
BACKGROUND: We assessed differences in predicted breast cancer (BC) mortality rates, across Europe, by 2020, taking into account changes in the time trends of BC mortality rates during the period 2000-2010. METHODS: BC mortality data, for 27 European Union (EU) countries, were extracted from the World Health Organization mortality database. First, we compared BC mortality data between time periods 2000-2004 and 2006-2010 through standardized mortality ratios (SMRs) and carrying out a graphical assessment of the age-specific rates...
July 19, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28718071/cancer-survival-in-adult-patients-in-spain-results-from-nine-population-based-cancer-registries
#4
M D Chirlaque, D Salmerón, J Galceran, A Ameijide, A Mateos, A Torrella, R Jiménez, N Larrañaga, R Marcos-Gragera, E Ardanaz, M Sant, P Minicozzi, C Navarro, M J Sánchez
INTRODUCTION: With the aim of providing cancer control indicators, this work presents cancer survival in adult (≥15 years) patients in Spain diagnosed during the period 2000-2007 from Spanish cancer registries participating in the EUROCARE project. METHODS: Cancer cases from nine Spanish population-based cancer registries were included and analysed as a whole. All primary malignant neoplasms diagnosed in adult patients were eligible for the analysis. Cancer patients were followed until 31 December 2008...
July 17, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28718070/platelet-lymphocyte-and-neutrophil-lymphocyte-ratios-are-prognostic-but-not-predictive-of-response-to-abiraterone-acetate-in-metastatic-castration-resistant-prostate-cancer
#5
A J Lozano Martínez, R Moreno Cano, S Escobar Páramo, R Salguero Aguilar, E Gonzalez Billalabeitia, R García Fernández, I De La Fuente Muñoz, A Romero Borque, M Porras Martínez, F Lopez Soler, E Cardenas Cánovas, I Ortega Martín
PURPOSE: Recently neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) have been reported to be inflammatory parameters that confer poorer outcome in metastatic castration-resistant prostate cancer (mCPRPC). However, these ratios have not been analyzed in patients treated with abiraterone acetate. We explored the relationship between different values of PLR and NLR and survival in mCPRCP treated with abiraterone and their possible relation with a prostate specific antigen (PSA) response...
July 17, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28710725/clinicopathologic-parameters-associated-with-postoperative-complications-and-risk-factors-for-tumor-recurrence-and-mortality-after-tumor-resection-of-patients-with-colorectal-cancer
#6
Z Bai, J Wang, T Wang, Y Li, X Zhao, G Wu, Y Yang, W Deng, Z Zhang
OBJECTIVE: To delineate the association of postoperative complications with clinicopathologic factors and to identify risk factors for tumor recurrence and mortality after tumor resection in patients with colorectal cancer (CRC). METHODS: The clinical data of 1144 patients with CRC who underwent surgical intervention between 2003 and 2013 were retrieved. Correlations of postoperative complications with clinicopathologic factors were examined using univariate analysis...
July 14, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28707036/treatment-strategies-for-rectal-cancer-with-synchronous-liver-metastases-surgical-and-oncological-outcomes-with-propensity-score-analysis
#7
H Salvador-Rosés, S López-Ben, P Planellas, E Canals, M Casellas-Robert, R Farrés, E Ramos, A Codina-Cazador, J Figueras
BACKGROUND: The optimal sequence of surgery for rectal cancer (RC) with synchronous liver metastases (SLM) is controversial. OBJECTIVES: The primary objective was to explore differences between the rectum first (RF) and the liver first strategy (LF) to achieve the complete resection (CR) of both tumors. METHODS: Patients diagnosed of RC with resectable or potentially resectable SLM were included. Data collected prospectively were analyzed with an intention-to-treat perspective, adjusting for between-sample differences (propensity score)...
July 13, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28702789/bevacizumab-plus-chemotherapy-for-patients-with-advanced-pulmonary-adenocarcinoma-harboring-egfr-mutations
#8
R-L Chen, H-J Chen, B-Y Jiang, X-C Zhang, Q Zhou, H-Y Tu, W-Z Zhong, Y-L Wu, J-J Yang
PURPOSE: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and bevacizumab plus chemotherapy were effective for EGFR-mutant patients. However, the appropriated treatment orders remained controvertible. We investigated the efficacy of treatment orders between bevacizumab plus chemotherapy and EGFR-TKIs for EGFR-mutant patients with advanced pulmonary adenocarcinoma. PATIENTS AND METHODS: This study involved 40 EGFR-mutant patients with advanced pulmonary adenocarcinoma who were treated with bevacizumab plus carboplatin and paclitaxel (Bev + CP) and EGFR-TKIs in different treatment orders or gemcitabine plus cisplatin (GP) in first-line setting...
July 12, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28695478/the-prognostic-impact-of-additional-intrathoracic-findings-in-patients-with-cancer-related-pulmonary-embolism
#9
P Jiménez-Fonseca, A Carmona-Bayonas, C Font, J Plasencia-Martínez, D Calvo-Temprano, R Otero, C Beato, M Biosca, M Sánchez, M Benegas, D Varona, L Faez, M Antonio, I de la Haba, O Madridano, M P Solis, A Ramchandani, E Castañón, P J Marchena, M Martín, F Ayala de la Peña, V Vicente
AIM: To assess the prevalence and prognostic significance of additional intrathoracic findings (AIFs) in patients with cancer and pulmonary embolism (PE). AIFs were considered alterations other than the characteristic ones intrinsic to PE or changes in cardiovascular morphology. METHODS: Subjects have been taken from a Spanish national multidisciplinary and multicenter study of PE and cancer who were treated between 2004 and 2015. The endpoint was the appearance of serious complications or death within 15 days...
July 10, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28681313/an-independent-survival-prognostic-role-for-human-epidermal-growth-factor-receptor-2-in-gastric-cancer-evidence-from-a-meta-analysis
#10
Y Wang, L He, Y Cheng
BACKGROUND: Some studies have suggested that human epidermal growth factor receptor 2 (HER2) positive is associated with poor outcomes in gastric cancer (GC), whereas another inconsistent studies make the situation confused. This meta-analysis was performed to determine whether HER2 played an independent prognostic role in clinicopathological characteristics and survival outcomes of GC. PATIENTS AND METHODS: Combination of GC and human epidermal growth factor 2 or HER2 or HER2/neu or erbB-2 or cerbB-2 or c-erbB2 or CD340 or p185 were used as key words...
July 5, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28674996/characteristics-of-adverse-drug-reactions-in-a-vemurafenib-early-post-marketing-phase-vigilance-study-in-japan
#11
H Uhara, Y Kiyohara, A Tsuda, M Takata, N Yamazaki
BACKGROUND: Post-approval research or monitoring is important to determine real-world safety of new products; however, evidence is scant for vemurafenib in Japanese patients. In Japan, a unique system is officially obligated to investigate post-approval safety. Here we report the first adverse drug reaction (ADR) data from vemurafenib-treated Japanese patients with metastatic melanoma. Data were collected in an early post-marketing phase vigilance (EPPV) study. METHODS: ADRs were events for which a causal relationship with vemurafenib could not be ruled out or was unknown...
July 3, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28667448/adjuvant-versus-salvage-radiotherapy-in-prostate-cancer-multi-institutional-retrospective-analysis-of-the-spanish-recap-database
#12
A Hervás, A Gómez-Caamaño, M Casaña, A Gómez-Iturriaga, J Pastor, J Jove, J L Mengual, C Gónzalez-San Segundo, J Muñoz
PURPOSE: To compare adjuvant radiotherapy (ART) to salvage radiotherapy (SRT) after radical prostatectomy (RP) in a cohort of prostate cancer (PCa) patients. The primary aim was to comparatively assess 2- and 5-year biochemical relapse-free survival (BRFS). A secondary aim was to identify predictors of survival. PATIENTS AND METHODS: Data were acquired from the RECAP database, a population-based prostate cancer registry in Spain. Inclusion criteria included RP (with or without lymphadenectomy) followed by ART or SRT...
June 30, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28660482/efficacy-of-tyrosine-kinase-inhibitors-in-egfr-mutant-lung-cancer-women-in-a-real-world-setting-the-world07-database
#13
J Remon, D Isla, P Garrido, J de Castro, M Majem, N Viñolas, A Artal, E Carcereny, M R García-Campelo, P Lianes, M Provencio, O Juan, P Diz, R Blanco, R Lopez-Castro, I Maestu, C Vadell, E Felip
BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer. METHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis. RESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited...
June 28, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28653276/histopathological-factors-predicting-response-to-neoadjuvant-therapy-in-gastric-carcinoma
#14
M L Sánchez de Molina, C Díaz Del Arco, P Vorwald, D García-Olmo, L Estrada, M J Fernández-Aceñero
BACKGROUND: Neoadjuvant therapy (NAT) is a useful therapeutic option. However, some patients respond poorly to it and can even show tumor progression. It is important to define factors that can predict response to NAT. MATERIALS AND METHODS: This is a retrospective cohort study to define histopathological factors predicting response to NAT in gastric tubular carcinoma. This study has enrolled 80 patients receiving chemotherapy for locally advanced gastric carcinoma...
June 26, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28646282/surgery-for-pancreatic-ductal-adenocarcinoma
#15
REVIEW
R Vera, L Díez, E Martín Pérez, J C Plaza, A Sanjuanbenito, A Carrato
Surgical resection is the only potentially curative option in the treatment of pancreatic ductal adenocarcinoma. Preoperative radiological imaging allows to rule out the presence of metastases. Three resectability categories are established based on the radiological findings depending on the degree of contact between the tumor and the blood vessels. Histological confirmation of malignancy is only required in cases of borderline or non-resectable tumors, prior to neoadjuvant treatment initiation. Diagnostic laparoscopy is recommended in the presence of large tumors of the body or tail and in borderline tumors to explore the possibility of resection and to apply treatment with curative intent, as well as in those cases with high level of biomarkers to rule out peritoneal involvement...
June 23, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28639051/adjuvant-treatment-for-pancreatic-ductal-carcinoma
#16
REVIEW
T Macarulla, T Fernández, M E Gallardo, O Hernando, A M López, M Hidalgo
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a very poor prognosis. Most of the patients are diagnosed in advanced stages of the disease, and 5-year survival rates in these patients remains <10%. Surgery still remains the only radical treatment option, although only 15-20% of patients are candidates for surgical resection at the time of the diagnosis. Patients who undergo radical surgery still have a limited survival rate, being the average of 23 months. Three clinical trials have shown that adjuvant chemotherapy therapy after surgery may improve survival: CONKO-1, ESPAC-3, and ESPAC-4...
June 21, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28631135/long-term-clinical-benefit-from-salvage-egfr-tyrosine-kinase-inhibitors-in-advanced-non-small-cell-lung-cancer-patients-with-egfr-wild-type-tumors
#17
F Koinis, A Voutsina, A Kalikaki, A Koutsopoulos, E Lagoudaki, E Tsakalaki, E K Dermitzaki, E Kontopodis, A G Pallis, V Georgoulias, A Kotsakis
BACKGROUND: Erlotinib has been approved for the management of NSCLC patients after failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is clearly associated with the presence of EGFR mutations, there is a subset of patients with EGFR wild-type (EGFRwt) tumors who impressively respond. PATIENTS AND METHODS: Patients with EGFRwt NSCLC who received salvage (≥2nd line) treatment with erlotinib for a prolonged period (>6 months), were sought from the database of the Hellenic Oncology Research Group...
June 19, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28623515/pancreatic-ductal-adenocarcinoma-metastatic-disease
#18
REVIEW
A J Muñoz Martín, J Adeva, J Martínez-Galán, J J Reina, M Hidalgo
The treatment of choice of metastatic PADC is systemic chemotherapy. In the last decade, there have been significant advances in this area. New combination poli-chemotherapy schemes have shown a significant increase in overall survival and progression-free survival without impairing quality of life. In addition, the value of second-line chemotherapy treatment has consolidated and a new concept called "therapeutic sequencing" has also emerged. The aim of this article is to review the different therapeutic options in metastatic PDAC based on patient's characteristics...
June 16, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28623514/the-potential-roles-of-bacteria-to-improve-radiation-treatment-outcome
#19
REVIEW
E Kouhsari, A Ghadimi-Daresajini, H Abdollahi, N Amirmozafari, S R Mahdavi, S Abbasian, S H Mousavi, H F Yaseri, M Moghaderi
Many combined therapies have been proposed to enhance radiotherapy outcome, but they have several limitations. As a new feasible strategy, combination of radiotherapy with bacteria showed a significant positive impact on the tumor treatment and metastasis inhibition. Although probiotic bacteria and radiotherapy alone can be effective in the treatment of different cancers, the combination of these two therapies seems to enhance therapeutic outcome and is cost-effective. Bacterial cells can act as therapeutic/gene/drug delivery vehicles as well as theranostic agents...
June 16, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28623513/the-spine-instability-neoplastic-score-sins-in-the-assessment-of-response-to-radiotherapy-for-bone-metastases
#20
E Gallizia, G Apicella, T Cena, M Di Genesio Pagliuca, L Deantonio, M Krengli
BACKGROUND: Vertebral metastases are often causing pain and spine instability. Radiotherapy is of significant benefit for painful spine metastases but the response can be very variable. The spine instability neoplastic score (SINS) is a recent classification system for diagnosis of spinal instability caused by vertebral metastases. We analysed the degree of pain relief, the need of drug therapy and the imaging features and the SINS before and after radiotherapy. In particular, we investigated the possible correlation of spine instability defined by pre-treatment SINS with pretreatment pain and with response to radiotherapy...
June 16, 2017: Clinical & Translational Oncology
journal
journal
41053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"